FGF7 and neoplasm: If these findings reflect the need to better define the appropriate dosing regimen [5] and/or the expression (and secretion) by tumor cells of other phosphatonins (e.g., MEPE, FGF7, sFRP-4) [1, 5, 16–18], it remains to be established.